top of page

FDA Approves Revolutionary Spinal Cord Stimulation Devices: Could This End Chronic Low Back Pain?

Revolutionary Spinal Cord Stimulation Devices: A New Hope for Chronic Low Back Pain Sufferers, Including 70-Year-Old Construction Worker

70 Year of Male with chronic Low back pain
Photo by Author using Wonder Digital Art


Oakland, California, is now where John calls home after dedicating most of his life to the construction industry. At 70, he has been contending with chronic low back pain in recent years. It has been challenging for him to find relief, even with pain medication. Regrettably, the drug has become an addiction he must wrestle with while striving to cope with the unrelenting pain.

Intrigued by the FDA officially approving spinal cord stimulation devices for chronic back pain, he mused over the news. It was hopeful, but more information was necessary for him to consider it a practical choice. The alluring prospect of a painless life tempted him, leading him to arrange an appointment with his medical professional to discuss the topic at length.

The FDA's recent inclusion of Abbott Laboratories' SCS products, namely the Proclaim SCS family without the need for recharge and the rechargeable Eterna SCS line, came as a total shock to their inventor.

The brain's perception of pain was successfully obstructed by the mild electrical energy discharged by the devices.

Thrilled by the exciting revelation that the DISTINCT study had revealed, John couldn't wait to try SCS treatments for his back pain. The study had significantly bolstered his hopes, indicating that patients who underwent this innovative treatment experienced a more remarkable quality of life, psychological well-being, back pain, and overall function than those who relied on conventional medical procedures. Upon trying it, John found that SCS effectively managed his persistent back pain.

The US Food and Drug Administration (FDA) has broadened the usage of Abbott Laboratories' spinal cord stimulation (SCS) technology to combat persistent back pain in individuals who are not eligible for back surgery or have yet to undergo it.

The latest indication covers all of Abbott's SCS devices in the US, including the Proclaim SCS family, which is recharge-free, and the rechargeable Eterna SCS platform.

The company's devices use a low-energy waveform called BurstDR, which is exclusive to them. By emitting mild electrical energy bursts, the waveform intercepts pain signals before they reach the brain without causing abnormal tingling sensations.

The DISTINCT study was initiated with 270 adults suffering from chronic back pain that hindered their daily routine for over a dozen years. These participants did not qualify for surgery and served as the foundation for the study. The outcome of this study gave credence to the expanded use of the medication.

Back pain, function, quality of life, and psychological state significantly improved for patients who received SCS treatment compared to those who underwent conservative medical management, as stated in the study. The number of patients benefiting from SCS was found to be higher.

Abbott's SCS gadgets, coupled with BurstDR stimulation, give medical professionals an unprecedented opportunity to resolve an untapped sector of chronic back pain patients, according to Dr. Timothy Deer, MD, the president and CEO of the Spine and Nerve Centers of the Virginias in Charleston, West Virginia. John's experience perfectly encapsulated this.

Discovering a treatment that freed him from painkillers, John's gratitude knew no bounds. It grew even more when he found a way to reclaim his life.

This story was created based on real-life events to inspire those suffering from low back pain.


bottom of page